Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$49.44
-$0.34(-0.44%)
At close: 4:00 PM EST
$49.44
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $94.99
Previous CloseN/A
Volume53.78K
Average Volume (3M)893.05K
Market Cap
$2.41B
Enterprise Value$4.50B
Total Cash (Recent Filing)$292.90M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)15.3
Beta0.77
Next Earnings
Nov 06, 2025EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding48,177,258
10 Day Avg. Volume606,811
30 Day Avg. Volume893,050
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.87
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda12.99
Forecast
1Y Price Target
$73.13Price Target Upside47.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
EPS PerformanceNon-GAAP EPS came in at $1.10, exceeding both the internal estimate and the consensus estimate of $1.02.
Investment RatingAnalyst maintains an OUTPERFORM investment rating on HAE shares with a price target of $86, indicating strong future potential.
Revenue PerformanceThe hospital segment is expected to deliver $148.4 million in revenue, marking a 7.2% increase compared to the same period a year ago.
Bears Say
Interventional Technologies DeclineThe interventional technologies business within the hospital unit declined 7.2% on a reported basis and was down 7.5% organically, rattling investors.
Market Share LossThe company lost material market share in around 50 of its 500 key EP hospital accounts as competitors ramped efforts to either take back share or capture share utilizing very aggressive pricing.
Top-line DeclineThe likely top-line decline is primarily due to the winddown of the CSL relationship in U.S. plasma and the recent divestiture activity in the company’s blood center business.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $47.31 and its highest was $94.98 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $2.41B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 06, 2025 which is in 6 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 07, 2025. The company reported $1.1 earnings per share for the quarter, beating the consensus estimate of $1.008 by $0.092.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.11.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 48,177,258 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.1 in its last earnings report, beating expectations of $1.008. Following the earnings report the stock price went down -26.58%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.13 (47.92% Upside)
$73.13 (47.92% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 93.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.36%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
-3.10%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation (HAE) is a global healthcare company that specializes in blood management solutions. Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics operates in various sectors including blood component collection, transfusion medicine, and surgical blood management. Its core products and services include automated blood collection systems, blood processing equipment, and software solutions designed to enhance the efficiency and safety of blood management practices in hospitals and blood centers worldwide.
HAE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong performance in key growth areas, particularly in the plasma and hemostasis management segments, with significant margin expansion and strategic share buybacks contributing to earnings growth. However, challenges remain in the interventional technologies and overall revenue declined due to portfolio transitions. The company is optimistic about overcoming these challenges with strategic initiatives.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$73.13
▲(47.92% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
41.75% Mutual Funds
0.72% Other Institutional Investors
31.20% Public Companies and
Individual Investors